Given that MEF2C was found to affect prognosis, immune infiltration and stemness in osteosarcoma patients in our previous study, we verified the expression of MEF2C in clinical tissues of osteosarcoma patients by immunohistochemical experiments. This evidence concerns the gene MEF2C and osteosarcoma.